Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Xenograft Model Antitumor Assays"" wg kryterium: Temat


Tytuł:
Characterization of a novel recombinant calcium-binding protein from Arca subcrenata and its anti-hepatoma activities in vitro and in vivo.
Autorzy:
Shi H; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China.
Panjikar S; ANSTO, Australian Synchrotron, Melbourne, Victoria, Australia.
Li C; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China.
Ou X; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China.
Zhou Y; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Zhang K; Department of Life Science, Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201204, China.
Song L; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China.
Yu R; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China; Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China. Electronic address: .
Sun L; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Zhu J; Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou 510632, China; Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China. Electronic address: .
Pokaż więcej
Źródło:
International journal of biological macromolecules [Int J Biol Macromol] 2023 Aug 01; Vol. 245, pp. 125513. Date of Electronic Publication: 2023 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
Bivalvia*/chemistry
Calcium-Binding Proteins*/genetics
Calcium-Binding Proteins*/metabolism
Calcium-Binding Proteins*/pharmacology
Calcium-Binding Proteins*/therapeutic use
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Recombinant Proteins*/genetics
Recombinant Proteins*/metabolism
Recombinant Proteins*/pharmacology
Recombinant Proteins*/therapeutic use
Xenograft Model Antitumor Assays*
Animals ; Humans ; Mice ; Binding Sites ; Cell Proliferation/drug effects ; Competitive Bidding ; Crystallography, X-Ray ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Escherichia coli ; Hep G2 Cells ; Hydrogen Bonding ; Molecular Dynamics Simulation ; Signal Transduction ; Molecular Docking Simulation
Czasopismo naukowe
Tytuł:
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies.
Autorzy:
Xue B; Cypre, Inc., South San Francisco, CA 94080, USA.
Schüler J; Charles River Discovery Research Services Germany GmbH, 79108 Freiburg, Germany.
Harrod CM; Cypre, Inc., South San Francisco, CA 94080, USA.
Lashuk K; Charles River Discovery Research Services Germany GmbH, 79108 Freiburg, Germany.
Bomya Z; Cypre, Inc., South San Francisco, CA 94080, USA.
Hribar KC; Cypre, Inc., South San Francisco, CA 94080, USA.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Apr 13; Vol. 12 (8). Date of Electronic Publication: 2023 Apr 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hydrogels*
Tumor Microenvironment*
Cell Culture Techniques, Three Dimensional*
Xenograft Model Antitumor Assays*/methods
Antineoplastic Agents, Immunological*/isolation & purification
Antineoplastic Agents, Immunological*/pharmacology
Antineoplastic Agents, Immunological*/therapeutic use
Stromal Cells ; Neoplasms/drug therapy ; Humans ; Immunotherapy ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer.
Autorzy:
Fukushima H; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Takao S; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Furusawa A; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Valera Romero V; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Gurram S; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Kato T; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Okuyama S; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Kano M; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Choyke PL; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Kobayashi H; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA. Electronic address: .
Pokaż więcej
Źródło:
Cancer letters [Cancer Lett] 2024 Mar 31; Vol. 585, pp. 216606. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Photosensitizing Agents*/pharmacology
Photosensitizing Agents*/therapeutic use
Urinary Bladder Neoplasms*/drug therapy
Humans ; Nectins/genetics ; Cell Line, Tumor ; Phototherapy/methods ; Immunotherapy/methods ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Integrated proteogenomic characterization of glioblastoma evolution.
Autorzy:
Kim KH; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Proteomics Core Facility, Research Core Center, Research Institute, National Cancer Center, Goyang, Korea.
Migliozzi S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Koo H; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Hong JH; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Park SM; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Kim S; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Kwon HJ; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Ha S; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Garofano L; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Oh YT; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
D'Angelo F; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Kim CI; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Kim S; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Lee JY; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Kim J; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Hong J; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jang EH; Laboratory of Neuroscience, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea.
Mathon B; Service de Neurochirurgie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.
Di Stefano AL; Institut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France; Department of Neurology, Foch Hospital, Suresnes, France.
Bielle F; Institut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
Laurenge A; Institut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
Nesvizhskii AI; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Hur EM; Laboratory of Neuroscience, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea; BK21 Four Future Veterinary Medicine Leading Education & Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Korea.
Yin J; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
Shi B; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
Kim Y; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Moon KS; Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Korea.
Kwon JT; Department of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Lee SH; Department of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Lee SH; Department of Neurosurgery, Eulji University School of Medicine, Daejeon, Korea.
Gwak HS; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Lasorella A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA.
Yoo H; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Sanson M; Institut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France. Electronic address: .
Sa JK; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea. Electronic address: .
Park CK; Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. Electronic address: .
Nam DH; Department of Neurosurgery and Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: .
Iavarone A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Neurological Surgery and Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: .
Park JB; Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2024 Mar 11; Vol. 42 (3), pp. 358-377.e8. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/genetics
Proteogenomics*
Brain Neoplasms*/genetics
Animals ; Humans ; Proto-Oncogene Proteins B-raf ; Proteomics ; Cell Line, Tumor ; Neoplasm Recurrence, Local ; Disease Models, Animal ; Drug Resistance, Neoplasm ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs).
Autorzy:
Patel KR; Department of Pathology and Immunology, Anatomic Pathology Division, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA. Electronic address: .
Espinoza AF; Department of General Surgery, Division of Pediatric Surgery, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Urbicain M; Department of Pathology and Immunology, Genomic Medicine Division, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Patel RH; Department of General Surgery, Division of Pediatric Surgery, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Major A; Department of Pathology and Immunology, Anatomic Pathology Division, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Sarabia SF; Department of Pathology and Immunology, Genomic Medicine Division, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Lopez-Terrada D; Department of Pathology and Immunology, Genomic Medicine Division, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Vasudevan SA; Department of General Surgery, Division of Pediatric Surgery, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Woodfield SE; Department of General Surgery, Division of Pediatric Surgery, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Pokaż więcej
Źródło:
Pathology, research and practice [Pathol Res Pract] 2024 Mar; Vol. 255, pp. 155163. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Child ; Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Heterografts ; Ki-67 Antigen
Czasopismo naukowe
Tytuł:
5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells.
Autorzy:
Chen HC; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kuo CY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chang Y; Department of Obstetrics and Gynecology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.; School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Tsai DL; Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Division of Chest Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Lee MH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Lee JY; Division of Chest Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Lee HM; Division of General Surgery, Department of Surgery, E-Da Cancer Hospital, Kaohsiung, Taiwan.; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Su YC; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan. .; Division of Hematology-Oncology, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 22; Vol. 24 (1), pp. 248. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Tryptophan/*analogs & derivatives
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Cell Line, Tumor ; Cell Proliferation ; Xenograft Model Antitumor Assays ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Apoptosis
Czasopismo naukowe
Tytuł:
Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis.
Autorzy:
Morimoto T; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.; Department of Neurosurgery, Nara City Hospital, Nara 630-8305, Nara, Japan.
Nakazawa T; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.; Department of Neurosurgery, Nara City Hospital, Nara 630-8305, Nara, Japan.
Matsuda R; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Maeoka R; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Nishimura F; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Nakamura M; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.; Grandsoul Research Institute for Immunology, Inc., Uda 633-2221, Nara, Japan.
Yamada S; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Park YS; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Tsujimura T; Grandsoul Research Institute for Immunology, Inc., Uda 633-2221, Nara, Japan.
Nakagawa I; Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 19; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/therapy
Glioblastoma*/drug therapy
Brain Neoplasms*/therapy
Brain Neoplasms*/drug therapy
Humans ; Mice ; Animals ; Disease Models, Animal ; Transcriptome ; Heterografts ; Mice, Inbred NOD ; Killer Cells, Natural/metabolism ; Xenograft Model Antitumor Assays ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.
Autorzy:
Ye J; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Liu Q; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
He Y; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Song Z; Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, 518000, Guangdong, People's Republic of China.
Lin B; Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, 518000, Guangdong, People's Republic of China.
Hu Z; Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, 518000, Guangdong, People's Republic of China.
Hu J; Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, 518000, Guangdong, People's Republic of China.
Ning Y; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China. .
Cai C; Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, 518000, Guangdong, People's Republic of China. cheguo_.
Li Y; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 18; Vol. 22 (1), pp. 171. Date of Electronic Publication: 2024 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Stomach Neoplasms*/genetics
Stomach Neoplasms*/therapy
Receptors, Chimeric Antigen*/genetics
Receptors, Chimeric Antigen*/metabolism
Humans ; Animals ; Mice ; Interleukin-15/genetics ; Interleukin-15/metabolism ; Cell Line, Tumor ; Neoplasm Recurrence, Local/metabolism ; Immunotherapy, Adoptive/methods ; T-Lymphocytes ; Xenograft Model Antitumor Assays ; Tumor Microenvironment ; Membrane Proteins/metabolism ; Neoplasm Proteins/metabolism ; Nerve Tissue Proteins/metabolism
Czasopismo naukowe
Tytuł:
Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Autorzy:
Demeule M; Theratechnologies Inc., Montréal, QC, Canada.
Currie JC; Theratechnologies Inc., Montréal, QC, Canada.
Charfi C; Theratechnologies Inc., Montréal, QC, Canada.
Zgheib A; Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
Cousineau I; Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
Lullier V; Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
Béliveau R; Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
Marsolais C; Theratechnologies Inc., Montréal, QC, Canada.
Annabi B; Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 16; Vol. 15, pp. 1355945. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*
Nucleotidyltransferases*
Humans ; Mice ; Animals ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Cell Death
Czasopismo naukowe
Tytuł:
Autophagy inhibition improves the targeted radionuclide therapy efficacy of I-FAP-2286 in pancreatic cancer xenografts.
Autorzy:
Liu X; School of Public Health and Management, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.; Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China.
Li D; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Ma T; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Luo X; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Peng Y; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Wang T; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China. .
Zuo C; Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China. .
Cai J; School of Public Health and Management, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. .; Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 15; Vol. 22 (1), pp. 156. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Fluorodeoxyglucose F18*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Animals ; Humans ; Mice ; Autophagy ; Cell Line, Tumor ; Mice, Nude ; Positron Emission Tomography Computed Tomography ; Radioisotopes/pharmacology ; Radioisotopes/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo.
Autorzy:
Chen X; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Luo Z; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Hu Z; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Sun D; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
He Y; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Lu J; Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Chen L; Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Liu S; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Feb 15; Vol. 266, pp. 116082. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Osteosarcoma*/drug therapy
Osteosarcoma*/pathology
Bone Neoplasms*/drug therapy
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Mice ; Animals ; Pharmaceutical Preparations ; Structure-Activity Relationship ; Cell Proliferation ; Xenograft Model Antitumor Assays ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma.
Autorzy:
Yang Z; Institute of Biomedical Engineering and Technology, Academy for Engineering & Technology, Fudan University, Shanghai 200433, China.
Liu Y; Henan University of Chinese Medicine, Zhengzhou 200433 Henan, China.
Li H; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Tang Q; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yang B; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Shi Z; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Mao Y; Institute of Biomedical Engineering and Technology, Academy for Engineering & Technology, Fudan University, Shanghai 200433, China.; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Pokaż więcej
Źródło:
Biomacromolecules [Biomacromolecules] 2024 Feb 12; Vol. 25 (2), pp. 655-665. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Animals ; Mice ; Temozolomide/therapeutic use ; RNA, Small Interfering/genetics ; Drug Resistance, Neoplasm/genetics ; Combined Modality Therapy ; Cell Line, Tumor ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
Autorzy:
Wang B; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Qi FZ; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Chen P; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Qian LM; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Su HS; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Wang Y; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Wang CH; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Hou YX; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Zhang Q; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Li D; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY, 11439, USA.
Zhang SH; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Pokaż więcej
Źródło:
International journal of biological sciences [Int J Biol Sci] 2024 Feb 11; Vol. 20 (5), pp. 1634-1651. Date of Electronic Publication: 2024 Feb 11 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Prodrugs*/therapeutic use
Prodrugs*/pharmacology
Nitroimidazoles*
Phosphoramide Mustards*
Humans ; Animals ; Mice ; Cell Hypoxia/physiology ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Hypoxia
Czasopismo naukowe
Tytuł:
The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study.
Autorzy:
Alalikhan A; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ebrahimi S; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Aliee A; Clinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mirzavi F; Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Hashemy SI; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. .; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2024 Feb 10; Vol. 41 (3), pp. 70. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article
MeSH Terms:
Fluorouracil*/pharmacology
Fluorouracil*/therapeutic use
Colorectal Neoplasms*/pathology
Animals ; Mice ; Humans ; Aprepitant/pharmacology ; Xenograft Model Antitumor Assays ; Drug Synergism ; Apoptosis ; Cell Proliferation ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells.
Autorzy:
Mai D; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. .; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA. .
Boyce T; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Mehta A; Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.; The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.
Reff J; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.
Scholler J; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.
Sheppard NC; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Lab Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
June CH; Center for Cellular Immunotherapies, Perelman School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Lab Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 07; Vol. 14 (1), pp. 3113. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Mesothelin*
Immunotherapy, Adoptive*/methods
Humans ; Animals ; Mice ; T-Lymphocytes/metabolism ; Immunity ; Cytokines/metabolism ; Disease Models, Animal ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Tristetraprolin/genetics
Czasopismo naukowe
Tytuł:
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Autorzy:
Shabaneh TB; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Stevens AR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Stull SM; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Shimp KR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Seaton BW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Gad EA; Comparative Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jaeger-Ruckstuhl CA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Simon S; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Koehne AL; Experimental Histopathology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Price JP; Molecular Design and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Olson JM; Molecular Design and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Hoffstrom BG; Antibody Technology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jellyman D; Antibody Technology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Riddell SR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA .
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Feb 07; Vol. 12 (2). Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
T-Lymphocytes*
Immunotherapy, Adoptive*
Mice ; Humans ; Animals ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Mice, Inbred Strains
Czasopismo naukowe
Tytuł:
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Autorzy:
Kaneko MK; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Suzuki H; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Ohishi T; Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu 410-0301, Japan.; Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.
Nakamura T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Tanaka T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 05; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Breast Neoplasms*/drug therapy
Animals ; Female ; Humans ; Mice ; Cell Line, Tumor ; Heterografts ; Receptor, ErbB-2/immunology ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
DT-13 inhibits the proliferation of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling.
Autorzy:
Xie G; Department of Breast, Thyroid and Vascular Surgery, Chongqing University FuLing Hospital, Chongqing, People's Republic of China. Electronic address: .
Tong F; Department of Breast, Thyroid and Vascular Surgery, Chongqing University FuLing Hospital, Chongqing, People's Republic of China. Electronic address: .
Xu M; Department of Breast, Thyroid and Vascular Surgery, Chongqing University FuLing Hospital, Chongqing, People's Republic of China. Electronic address: .
Shu Y; Department of Clinical Laboratory, Chongqing University FuLing Hospital, Chongqing, People's Republic of China. Electronic address: .
Li Z; Central Laboratory, Chongqing University FuLing Hospital, Chongqing, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Feb 05; Vol. 695, pp. 149451. Date of Electronic Publication: 2023 Dec 30.
Typ publikacji:
Journal Article
MeSH Terms:
AMP-Activated Protein Kinases*/drug effects
AMP-Activated Protein Kinases*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/metabolism
Saponins*/pharmacology
Saponins*/therapeutic use
Animals ; Humans ; Mice ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Mice, Inbred BALB C ; Mice, Nude ; TOR Serine-Threonine Kinases/drug effects ; TOR Serine-Threonine Kinases/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.
Autorzy:
Liu X; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Liu L; Department of Neurosurgery, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Wu A; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Huang S; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xu Z; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zhang X; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Li Z; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Li H; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Dong J; Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Pokaż więcej
Źródło:
CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Feb; Vol. 30 (2), pp. e14599.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/pathology
Exosomes*/metabolism
Brain Neoplasms*/genetics
Adult ; Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Astrocytes/metabolism ; Stem Cells/metabolism ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; AlkB Enzymes ; Mitochondrial Proteins
Czasopismo naukowe
Tytuł:
Exploring the in vivo anti-cancer potential of Neosetophomone B in leukemic cells using a zebrafish xenograft model.
Autorzy:
Kuttikrishnan S; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, 3050, Qatar; College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Hasan M; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar.
Prabhu KS; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, 3050, Qatar.
El-Elimat T; Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Oberlies NH; Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, United States.
Pearce CJ; Mycosynthetix Inc., Hillsborough, NC, 27278, United States.
Alali FQ; College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Ahmad A; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, 3050, Qatar; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Pourkarimi E; Division of Genomics and Translational Medicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
Bhat AA; Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Yalcin HC; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. Electronic address: .
Uddin S; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, 3050, Qatar; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Laboratory of Animal Research Center, Qatar University, Doha, Qatar. Electronic address: .
Pokaż więcej
Źródło:
Experimental cell research [Exp Cell Res] 2024 Feb 01; Vol. 435 (1), pp. 113907. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Zebrafish*/metabolism
Neoplasms*
Animals ; Humans ; Heterografts ; Disease Models, Animal ; Cell Line, Tumor ; Xenograft Model Antitumor Assays
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies